Top US Secondary Hyperparathyroidism Treatment (SHPT) Companies

US Secondary Hyperparathyroidism Treatment (SHPT) Market size was valued at USD 6.51 Billion in 2024 and is poised to grow from USD 6.95 Billion in 2025 to USD 11.77 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026–2033).

Amgen Inc. holds 40% of the US secondary hyperparathyroidism therapy (SHPT) market thanks to its substantial strategic decisions and robust pharmaceutical portfolio. SHPT is treated with Sensipar (Cinacalcet), a well-liked medication from Amgen. Generic manufacturers have only recently begun to enter the market as a result of numerous treatments' expiration of their patents. Organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz are among the market players. SHPT market expansion is also anticipated to be fueled by expanding generic manufacturer competition during the anticipated time frame. 'Amgen Inc. (US)', 'AbbVie Inc. (US) ', 'Sanofi (France) ', 'OPKO Health, Inc. (US) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Viatris Inc. (US) ', 'Astellas Pharma Inc. (Japan) ', 'Kyowa Kirin Co., Ltd. (Japan) ', 'F. Hoffmann-La Roche AG (Switzerland) ', 'Dr. Reddy's Laboratories Ltd. (India) ', 'Cipla Inc. (India) ', 'Sandoz (Switzerland) ', 'Pfizer Inc. (US) ', 'Bristol Myers Squibb (US) ', 'Eli Lilly and Company (US) ', 'Novartis AG (Switzerland) ', 'Merck & Co., Inc. (US) ', 'Johnson & Johnson (US) ', 'GlaxoSmithKline plc (UK) ', 'AstraZeneca PLC (UK/Sweden)'

SHPT development occurs simultaneously with vitamin D deficiency. Over 97% of ESRD patients, according to OPKO Health, Inc., show signs of vitamin D deficiency, which is a key sign that SHPT is developing in the patient. As a result, it is anticipated that the increase in the number of chronic illnesses brought on by sedentary lifestyles will drive the SHPT treatment market in the United States. The secondary hyperparathyroidism (SHPT) treatment market in the United States is also significantly influenced by the government's initiative to develop standards for better treatment management. The control of biochemical indicators of mineral and bone metabolism, which have a strong epidemiologic connection to cardiovascular events and bone fractures, is the goal of SHPT therapy.

As medical professionals and clinical specialists have become more aware of the condition, the management plan for SHPT has been improved.The growth of the market for treatments for CKD and ESRD would benefit from the early detection and evaluation of secondary hyperparathyroidism for mineral metabolism. The market is expected to grow more quickly during the projection period because there will be fewer issues with SHPT management.

Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.